



## ASX Announcement

7 December 2023

*Not for release to US wire services or distribution in the United States*

### Results of Entitlement Offer

#### Key Highlights

- **Anatara has successfully completed its Entitlement Offer.**
- **Of the total \$1,055,334 in New Shares offered under the Entitlement Offer, approximately \$657,914 (before transaction costs) was raised leaving a shortfall of \$397,422. Of this \$397,422, \$297,723 has been placed under the partial underwriting arrangement with Taylor Collison and to certain sophisticated investors, leaving a residual shortfall amount of \$99,699 that is expected to be placed in the near future.**
- **Funds raised under the Entitlement Offer will be used by Anatara to proceed with Stage 2 of the GaRP-IBS trial after promising results from Stage 1 (see ASX announcements on 28 September and 17 October 2023).**

Anatara Lifesciences Limited (ASX: ANR) ("**Anatara**" or the "**Company**") is pleased to announce the completion of its Entitlement Offer. The Entitlement Offer closed on Friday, 1 December 2023.

On Friday, 3 November 2023, the Company offered eligible shareholders with a registered address in Australia and New Zealand on the record date, being Wednesday, 8 November 2023, the opportunity to subscribe for fully paid ordinary shares (**New Shares**) under a partially underwritten 2 for 5 pro rata non-renounceable entitlement offer at the price of \$0.022 per New Share (**Offer Price**) (**Entitlement Offer**). The Entitlement Offer opened at 9:00am (Melbourne time) on Monday, 13 November 2023.

In addition to each eligible shareholders' entitlement under the Entitlement Offer, eligible shareholders were offered the opportunity to apply for additional New Shares under a "top-up" facility (**Oversubscription Offer**). Under the Oversubscription Offer, eligible shareholders could apply for New Shares in excess of their Entitlement.

The Entitlement Offer successfully raised approximately \$657,914 from eligible shareholders. The Entitlement Offer was subscribed as follows:

|   |                       |
|---|-----------------------|
| <b>Acceptances by Eligible Shareholders</b>   | 25,389,776 New Shares |
| <b>Acceptances by Eligible Shareholders for additional New Shares under the Oversubscription Facility</b> | 4,515,340 New Shares  |
| <b>Shortfall (prior to take-up by Underwriter and placement of Shortfall to sophisticated investors)</b>  | 18,064,626 New Shares |
| <b>Shortfall (following take-up by Underwriter and placement of Shortfall to sophisticated investors)</b> | 4,531,775 New Shares  |

As detailed above, Taylor Collison Limited (“**Taylor Collison**”) will take up or place 12,532,851 New Shares under the shortfall in accordance with its partial underwriting arrangement with Anataara (after accounting for Valid Applications received by the Company for Entitlement Shares subscribed to by clients of Taylor Collison). In addition, the Company has received commitments for a further 1,000,000 New Shares to be placed to certain sophisticated investors.

On the basis of the \$657,914 received from eligible shareholders under the Entitlement Offer and commitments for the shortfall amount, as detailed above, as at the date of this announcement this will raise a total of \$955,637.

The New Shares to be issued under the Entitlement Offer will rank equally in all respects with existing fully paid ordinary shares. Settlement of the Entitlement Offer is scheduled to occur on Thursday, 7 December 2023, with New Shares expected to be allotted on Friday, 8 December 2023, and trading to commence on a normal settlement basis on the Australian Securities Exchange (ASX) on the following trading day.

Commenting on the Entitlement Offer, Anataara's Executive Chairman, Dr David Brookes commented *“Following the successful Stage 1 of the Phase II IBS Trial results, it is very pleasing to see such strong support for the Entitlement Offer from existing shareholders. The Company is confident of quickly placing the remaining shortfall and is well placed to commence Stage 2 of the IBS trial with results anticipated in mid-CY24. We continue to execute on the commercial pathway for the GaRP product to provide relief and control for IBS sufferers and those with other gastrointestinal considerations.”*

### **Indicative Timetable**

Below is the current indicative timetable for completion of the Entitlement Offer.

| <b>Item</b>   | <b>Date</b>  |
|---|--|
| Announcement of Entitlement Offer results           | Thursday, 7 December 2023                                  |
| Entitlement Offer – Settlement Date                 | Thursday, 7 December 2023                                  |
| Issue Date – New Shares under the Entitlement Offer | Before 12.00pm (Melbourne time)<br>Friday, 8 December 2023 |
| Despatch Date                                       | Monday, 11 December 2023                                   |
| Trading in New Shares under the Entitlement Offer   |  |
| Issue Date – New Shares under the shortfall         | Monday, 11 December 2023                                   |

This timetable is indicative only and may be subject to change without notice to, or consultation with, you. Anataara reserves the right to amend any or all of these dates and times subject to the *Corporations Act 2001* (Cth), the ASX Listing Rules and other applicable laws.

This announcement has been approved by the Board of Anataara Lifesciences Limited.

—ENDS—

### **For more information please contact:**

#### **General inquiries**

David Brookes  
Chair, Anataara Lifesciences Ltd  
+61 (0) 411 712 579  
[dbrookes@anataara.com](mailto:dbrookes@anataara.com)

Dirk van Dissel  
Candour Advisory – Investor Relations  
+61 (0) 408 326 367  
[dirk@candouradvisory.com.au](mailto:dirk@candouradvisory.com.au)

### **About Anataara Lifesciences Ltd**

Anataara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anataara is a life sciences company with expertise in

developing products for animal and human health. Anantara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

## **Disclaimer**

### **Forward looking statements**

This document contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this document are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of Anantara, its directors and management. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of Anantara's business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of Anantara, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this document. The forward-looking statements are based on information available to Anantara as at the date of this document. Except as required by law or regulation (including the ASX Listing Rules), none of Anantara, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

### **Not an offer in the United States**

This document has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or in any other jurisdiction in which such an offer would be illegal. Any securities described in this document have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "US Securities Act") or the securities laws of any state or jurisdiction of the United States. Accordingly, the securities described in this document may not be offered or sold, directly or indirectly, in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and applicable securities laws of any state or other jurisdiction of the United States.